243984-26-1

Basic information

• Product Name: ethyl 2-(chlorosulfonyl)cyclohex-1-enecarboxylate
• Synonyms: ethyl 2-(chlorosulfonyl)cyclohex-1-enecarboxylate
• CAS NO: 243984-26-1
• Molecular Weight: 252.719
• Mol File: 243984-26-1.mol

Chemical Properties

• Melting Point: 32-33 °C(Solv: ethyl acetate (141-78-6))
• Boiling Point: 347.6±42.0 °C(Predicted)
• Density: 1.35±0.1 g/cm3(Predicted)
• CAS DataBase Reference: ethyl 2-(chlorosulfonyl)cyclohex-1-enecarboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 2-(chlorosulfonyl)cyclohex-1-enecarboxylate(243984-26-1)
• EPA Substance Registry System: ethyl 2-(chlorosulfonyl)cyclohex-1-enecarboxylate(243984-26-1)

Safety Data

• Hazardous Substances Data: 243984-26-1(Hazardous Substances Data)

Upstream product

• 243984-25-0 2-(ethoxycarbonyl)cyclohex-1-ene-1-sulfonic acid 
• 54928-91-5 ethyl 2-mercaptocyclohex-1-ene-1-carboxylate 
• 122135-83-5 ethyl 2-trifluoromethanesulfonyloxycyclohex-1-enecarboxylate 
• 1655-07-8 ethyl 2-oxocyclohexane carboxylate 

Downstream Products

• 243983-42-8 ethyl 6-[N-(4-chloro-2-fluorophenyl)sulfamoyl]-1-cyclohexene-1-carboxylate 
• 243983-44-0 d-ethyl 6-[N-(2,4-difluorophenyl)sulfamoyl]-1-cyclohexene-1-carboxylate 
• 243983-70-2 ethyl (6RS)-6-[N-(2-chloro-4-fluorophenyl)sulfamoyl]cyclohex-1-ene-1-carboxylate 

Relevant articles and documents

Preparation method 2 - (chlorosulfonyl) cyclohexane -1 - allyl formate derivative

The invention relates to a preparation method of 2 - (chlorosulfonyl) cyclohexane -1 - allyl formate derivative, which comprises the following steps: 1) dissolving the compound of formula III in an organic solvent; and reacting the compound of formula IV

DIRECTED CONJUGATION TECHNOLOGIES

Among other things, the present disclosure provides technologies for site-directed conjugation of various moieties of interest to target agents. In some embodiments, the present disclosure utilizes target binding moieties to provide high conjugation efficiency and selectivity. In some embodiments, provided technologies are useful for preparing antibody conjugates.

Synthesis and rational design of anti-inflammatory compounds: N-phenyl-cyclohexenyl sulfonamide derivatives

The synthesis of (±)-ethyl 6-[N-(2-chloro-4-fluorophenyl)sulfamoyl] cyclohex-1-ene-1-carboxylate (5n) has been reproduced from a method previously described and served as the background for the preparation of a nitro derivative, potentially useful as an a

SUBSTITUTED CYCLOHEXENES

Disclosed herein are substituted cyclohexene TLR4 signaling pathway modulators of Formula I, process of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.

SUBSTITUTED CYCLOHEXENES

Disclosed herein are deuterated derivatives of TAK-242 of Formula (I) which are modulators of TLR4 signalling pathway, pharmaceutical compositions thereof and methods of use thereof. Formula (I)

Discovery of novel and potent small-molecule inhibitors of NO and cytokine production as antisepsis agents: Synthesis and biological activity of alkyl 6-(N-substituted sulfamoyl)cyclohex-1-ene-1-carboxylate

To develop a new therapeutic agent for sepsis, screening of the Takeda chemical library was carried out using mouse macrophages stimulated with lipopolysaccharide (LPS) to identify a new class of small-molecule inhibitors of inflammatory mediator production. The lead compound 5a was discovered, from which a series of novel cyclohexene derivatives I bearing a sulfamoyl and ester group were designed, synthesized and tested for their inhibitory activity against nitric oxide (NO) production. Derivatives I were synthesized by the coupling of sulfonyl chlorides and anilines with concomitant double bond migration in the presence of triethylamine, and phenyl ring substitution and modification of the ester and cyclohexene moieties were carried out. Among the compounds synthesized, ethyl (6R)-6-[N-(2-chloro-4-fluorophenyl)sulfamoyl]- cyclohex-1-ene-1-carboxylate [(R)-(+)-5n, TAK-242] was found to exhibit the most potent suppressive activity for the production of not only NO but also inflammatory cytokines, such as tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) induced by LPS-stimulated mouse macrophages with IC 50 values of 1.8, 1.9 and 1.3 nM, respectively. It shows marked beneficial effects in vivo also. Intravenous administration of (R)-(+)-5n at doses of 0.1 mg/kg or more suppressed the production of NO and various cytokines [TNF-α, IL-6 and IL-1β] in the mouse endotoxin shock model. Furthermore, it protected mice from death dose-dependently and all mice survived at a dose of 3 mg/kg. The minimum effective dose to protect mice from lethality in this model was 0.3 mg/kg, which was consistent with those for inhibitory effects on the production of NO and cytokines. Compound CR)-(+)-5n is currently undergoing clinical trials for the treatment of sepsis.

Cycloalkene derivatives, process for producing the same, and use

The present invention provides a compound represented by the formula: wherein R represents an aliphatic hydrocarbon group optionally having substituents, an aromatic hydrocarbon group optionally having substituents, a heterocyclic group optionally having